Teva to list shares on New York Stock Exchange
JERUSALEM — Israel-based Teva Pharmaceutical Industries is switching stock exchanges, the company said.
The world’s largest generic drug manufacturer — and increasingly a player in branded and specialty drugs — announced Wednesday that it would transfer the listing of its shares from the Nasdaq to the New York Stock Exchange, with plans to start trading on the NYSE on May 30 under its current ticker symbol, "TEVA."
"Teva is a global pharmaceutical company that combines important generic and specialty pharmaceuticals businesses, as well as an expanding over-the-counter products franchise," Teva chairman Phillip Frost said. "As we continue to grow, the NYSE, the world’s largest stock exchange will provide a state-of-the-art trading platform, as well as greater market reach. We are proud to take our place on the NYSE alongside many of our key customers, suppliers and peers."
The news closely follows Monday’s announcement by another Israeli generic drug manufacturer, Taro Pharmaceutical Industries, that it would begin listing shares on the NYSE starting on Thursday. Taro had been listing shares on the over-the-counter Pink Sheet markets.
Novartis launches Arcapta Neohaler
EAST HANOVER, N.J. — Novartis has launched a new treatment for chronic obstructive pulmonary disease, the drug maker said Monday.
Novartis Pharmaceuticals, the U.S. division of the Swiss drug manufacturer, announced the launch of Arcapta Neohaler (indacaterol inhalation powder) in the 75-mcg strength. The Food and Drug Administration approved the drug last July.
The company said the inhaler is designed for the long-term maintenance bronchodilator treatment of airflow obstruction in adults with COPD, which includes the diseases chronic bronchitis and emphysema, though the drug is not approved by the FDA for treating asthma.
Walgreens launches health-and-wellness database from its Facebook page
ATLANTA — Walgreens on Tuesday partnered with the online platform Sharecare on the launch of a new "Answers" application, which provides access to a comprehensive and searchable drug, supplement and wellness database on Facebook.
The application, which is integrated into Walgreens’ Facebook page, gives Walgreens nearly 2 million followers convenient access to an interactive portal containing health information and resources.
"With the success of our online health initiatives, such as the ability to chat live with a Walgreens pharmacist 24/7, this is yet another example of our commitment to innovation in the digital space that gives people greater access to Walgreens pharmacists and other clinical experts," Walgreens president of e-commerce Sona Chawla said. "Our relationship with Sharecare further extends our Answers promise beyond Walgreens retail locations, providing important healthcare information to customers online, through mobile applications and social media."
In addition to existing applications on the Walgreens Facebook page offering health advice and cost-saving tips, the Answers section provides seamless integration to Sharecare.com content for Walgreens followers. Answers features information related to a broad range of health topics, including prescription drugs, disease symptoms, at-home remedies and over-the-counter recommendations.
As part of its relationship with Sharecare, Walgreens pharmacists will provide answers to the thousands of frequently-asked health questions.